A prognostic index for multiple myeloma
1996

Prognostic Index for Multiple Myeloma

Sample size: 231 publication Evidence: high

Author Information

Author(s): G Grignani, PG Gobbi, R Formisano, C Pieresca, G Ucci, S Brugnatelli, A Riccardi, E Ascari

Primary Institution: Universita di Pavia, IRCCS Policlinico S. Matteo, Pavia, Italy

Hypothesis

Can clinical characteristics at diagnosis and response to first-line chemotherapy improve the prognostic forecast in multiple myeloma patients?

Conclusion

The study proposes a new scoring system that effectively identifies different risk classes among multiple myeloma patients, improving prognosis estimation.

Supporting Evidence

  • The proposed scoring system identified three risk classes with median overall survival of 52, 28, and 13 months.
  • Three variables were found to be independently significant: the British Medical Research Council staging system, bone marrow plasma cell percentage, and response to therapy.
  • Statistical analysis showed that the new prognostic model was highly significant.

Takeaway

Doctors can better predict how long patients with multiple myeloma will live by looking at their initial health and how they respond to treatment.

Methodology

231 patients were randomized in a multicenter trial to different therapies based on their disease stage, and their clinical features were analyzed for prognostic variables.

Limitations

The study's findings may not apply to all multiple myeloma patients due to the heterogeneity of the disease.

Participant Demographics

{"mean_age":65,"male":120,"female":111}

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication